Results

Total Results: 2,279 records

Showing results for "factor".

161. Data Points #8: Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension, 2007 to 2009 | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/hypertension-drugs-utilization/research
     December 01, 2019 - Hypertension is a risk factor for numerous pathologic conditions, including heart attack, heart failure

162. Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non-ST Elevation Myocardial Infarction | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/angina-heart-attack-treatments/research-protocol
     December 01, 2019 - Fondaparinuxis an indirect factor Xa inhibitor that is injected subcutaneously on a daily basis. … effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept … effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept

163. Assessing the Impact of Economic Evidence on Policymakers in Health Care — A Systematic Review | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/economic-evidence/research
     November 01, 2017 - evidence: (1) quality and transparency of the studies that provided the economic evidence was a promoting factor

164. Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/methods-guidance-quantitative-synthesis/methods
     December 01, 2019 - events become more frequent (5 percent to 10 percent), the Mantel-Haenszel method (without correction factor … Considerations of correction factor for studies with zero events in one arm. … method, the Mantel-Haenszel method, or a logistic regression approach, without adding a correction factor … For the Mantel-Haenszel method, a correction factor of 0.5 is not recommended but using no correction … factor or alternative correction factors could be considered, and investigated in sensitivity analyses

165. Safety of Vaccines Used for Routine Immunization in the United States | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/vaccine-safety/research
     April 01, 2020 - of post-licensure analyses: case-control studies, self-controlled case series, and multivariate risk factor

166. Misuse of Prescription Stimulants in Adults (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/misuse-prescription-protocol.pdf
     September 13, 2024 - Quality In Prognosis Studies (QUIPS) tool13 which covers study participation, attrition, prognostic factor … Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework

167. Layout 1 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cancer-anemia_executive.pdf
     May 01, 2006 - Neither higher than recommended target Hb nor any other single patient- or treatment- related factor … select patients or predict responses to treatment Available evidence does not identify any single factor

168. Dia 1 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
     January 01, 2011 - scenarios and if a respondent picks all these scenarios we can assume Thai food is an important factor

169. Data Points #14: Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/dcis-endocrine-therapy/research
     December 01, 2019 - In addition, about 60,000 women were diagnosed with ductal carcinoma in situ (DCIS), a possible risk factor

170. PowerPoint Presentation (ppt file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/medical-test-reviews-frameworks.ppt
     June 01, 2012 - screen-film mammography in breast cancer screening Project 2 (add-on test): Human epidermal growth factor … replacement for screening film mammography. - The add-on test example uses a human epidermal growth factor … Initial ambiguous claim: Amplification and protein expression assays of the human epidermal growth factor … It involves the use of a human epidermal growth factor receptor 2 (HER2) gene amplification assay after … a refined claim that patients with equivocal results for over expression of human epidermal growth factor

171. PowerPoint Presentation (ppt file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/medical-test-reviews-frameworks.ppt
     June 01, 2012 - screen-film mammography in breast cancer screening Project 2 (add-on test): Human epidermal growth factor … replacement for screening film mammography. - The add-on test example uses a human epidermal growth factor … Initial ambiguous claim: Amplification and protein expression assays of the human epidermal growth factor … It involves the use of a human epidermal growth factor receptor 2 (HER2) gene amplification assay after … a refined claim that patients with equivocal results for over expression of human epidermal growth factor

172. Mosquito Bites | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/mosquito-bites
     One factor is climate change , which makes the conditions in some parts of the United States more favorable

173. Drug Therapy for Early Rheumatoid Arthritis in Adults – An Update | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/rheumatoid-arthritis-medicine-update/research-protocol
     September 01, 2019 - Rates of RA development are increased in monozygotic twins, implicating genetics as a contributing factor … disease activity remains moderate or high, double or triple combination DMARDs or a tumor necrosis factor … Food and Drug Administration; RA = rheumatoid arthritis; TNF = tumor necrosis factor; ts = targeted synthetic … disease-modifying antirheumatic drug; KQ = Key Question; RA = rheumatoid arthritis; TNF = tumor necrosis factor … rheumatoid arthritis; RCT = randomized controlled trial; SR = systematic review; TNF = tumor necrosis factor

174. - (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_appendixes.pdf
     January 01, 2009 - Modulating effect of human growth hormone on tumour necrosis factor-alpha and interleukin- 1beta. … Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor … Insulin-Like Growth Factor 1 (IGF-1): Protein hormone responsible for growth and development. … growth factors including insulin-like growth factor 1 (IGF-1). … Stature as a prognostic factor in cystic fibrosis survival.

175. Measuring Documentation Burden in Healthcare | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/documentation-burden/prepub-tech-brief
     March 01, 2025 - health record systems (EHR) have ushered an increasing documentation burden, frequently cited as a key factor

176. Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/cancer-pancreas/research-protocol
     January 01, 2020 - /or clinical followup 1e P1 Patient factors or tumor characteristics Comparator patient factor … Sedation-related effects of EUS-FNA (e.g., nausea, vomiting) 3a P1 or P2 or P3 Patient factor … Comparator patient factor See the list of harms for KQ 3 3b P1 or P2 or P3 Same list as … An important factor in selecting an imaging modality is the availability and accessibility of that modality … Although this factor will not be addressed formally in the review as a KQ, we plan to collect and provide

177. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
     December 11, 2012 - Fondaparinux is an indirect factor Xa inhibitor that is injected subcutaneously on a daily basis. … OR effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept … OR effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept

178. Screening for and Management of Chronic Kidney Disease Stages 1-3 | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/kidney-disease-medicine/research-protocol
     December 01, 2019 - subgroups of people; (3) Whether the feasibility, efficacy, and/or harms of treatment for the risk factor … filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor

179. Conducting Quantitative Synthesis when Comparing Medical Interventions: AHRQ and the Effective Health Care Program (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-quantitative-synthesis_methods.pdf
     October 01, 2010 - events become more frequent (5 percent to10 percent), the Mantel-Haenszel method (without correction factor … Considerations of correction factor for studies with zero events in one arm. … method, the Mantel-Haenszel method, or a logistic regression approach, without adding a correction factor … For the Mantel-Haenszel method, a correction factor of 0.5 is not recommended but using no correction … factor or alternative correction factors could be considered, and investigated in sensitivity analyses

180. Conducting Quantitative Synthesis when Comparing Medical Interventions: AHRQ and the Effective Health Care Program (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/methodsguide_conductingquantitativesynthesis.pdf
     October 01, 2010 - events become more frequent (5 percent to10 percent), the Mantel-Haenszel method (without correction factor … Considerations of correction factor for studies with zero events in one arm. … method, the Mantel-Haenszel method, or a logistic regression approach, without adding a correction factor … For the Mantel-Haenszel method, a correction factor of 0.5 is not recommended but using no correction … factor or alternative correction factors could be considered, and investigated in sensitivity analyses